The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Danaher Corporation (NYSE:DHR) is one of the 10 Unrivaled Stocks of the Next 5 Years. On April 14, Barclays reduced its price target on Danaher Corporation (NYSE:DHR) from $250 to $230 and maintained its Overweight rating on the stock.

The research firm adjusted price targets for the life sciences and diagnostic tools sector as part of its first-quarter preview. While Barclays remains positive about the overall setup for the sector, it noted that it is “not without risk.” The firm also highlighted that investor sentiment is at all-time low levels but it continues to support the “last-cut thesis (for the most part).”

Earlier, on April 6, Evercore ISI analyst Vijay Kumar also cut the firm’s price target on Danaher Corporation (NYSE:DHR) from $254 to $225 and maintained an Outperform rating on the stock.

Danaher Corporation (NYSE:DHR) was also added to Evercore ISI’s “Tactical Outperform” list as part of the firm’s Q1 preview for medical technology and life science tools companies.

Danaher Corporation (NYSE:DHR) is a leading global life sciences and diagnostics innovation company. The company is known for its professional, medical, research, and industrial products and services that help discover, develop, and deliver life-changing therapies.

While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Performing AI Stocks to Buy and 10 Best Performing Blue Chip Stocks to Buy.

Disclosure: None.  Follow Insider Monkey on Google News.